{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older",
    "geneContextQualifier": "--",
    "objectTherapeutic": "Daunorubicin and cytarabine liposome [Vyxeos]"
}